SS-31 is the only peptide in this class with FDA approval — granted in 2025 as Forzinity for Barth syndrome, a rare mitochondrial cardiomyopathy. What earned approval is also what makes it relevant off-label: it's structural repair for the mitochondria you already have, not pharmacological override. Distinct from MOTS-c (which retrains metabolic signaling), SS-31 fixes existing infrastructure; in the Mito Stack they're complementary, with NAD+ as the redox currency both consume. Strongest case: chronic fatigue where mitochondrial membrane damage is the bottleneck, support during GLP-1 fat loss, and as the structural foundation of the Mito Stack.

What Is SS-31 (Elamipretide)?

A short peptide (D-Arg-Dmt-Lys-Phe-NH₂) that concentrates inside mitochondria ~5,000× higher than surrounding tissue, reaching the inner membrane where energy production happens. Its target is cardiolipin, a lipid unique to the inner membrane that holds the energy-producing complexes in position.

How Mitochondria Break Down

The inner membrane loosens over time under small but cumulative pressures — each erodes the structure energy production depends on.

How SS-31 Works

It binds cardiolipin and restores the structural tension that keeps energy machinery aligned. Once structure is recovered: electron flow becomes cleaner (respiratory complexes stay in position, less electron leak); the membrane holds its charge more reliably (sustaining the gradient for ATP); mitochondria experience less internal strain (fewer reactive oxygen species, longer functional life); and tissues meet demand with proportionate fatigue. These are structural corrections, not forced output — SS-31 restores the architecture that makes clean energy possible.

Benefits

Energy stability: physical effort produces proportional fatigue instead of delayed crashes; daily variability narrows. ATP in aging: a single IV dose increased skeletal-muscle ATP production in older adults (target engagement in the most-affected population). Cardiac function: improved mitochondrial respiration in failing human heart tissue; Barth-syndrome trials showed multi-year improvements in cardiac biomarkers and functional capacity (the FDA-approval basis). NAD+ conservation: by fixing structural problems, SS-31 reduces the NAD+ burn rate — less electron leak, less PARP repair work, lower CD38 — so NAD+ stays higher.

Dosing

SS-31 is a structural repair signal, not continuous therapy — once membrane sites are saturated, more doesn't help. Reconstitute with isotonic (sodium-chloride) BAC water; see the reconstitution calculator.

Biohacker doses (5–10 mg) are lower than clinical-trial doses (40 mg) because trial populations had severe cardiolipin dysfunction requiring rescue, whereas healthy aging mitochondria have intact infrastructure needing only stabilization — 5–10 mg reaches binding saturation, and higher offers diminishing return. Timing: morning or 60–90 min before training, used intermittently. Expect a Day 3–4 flat/fatigued pattern during loading (the repair process) before the shift to steadier energy on day 4–5 — don't quit mid-adaptation.

Clinical Research and FDA Approval

SS-31 received FDA accelerated approval in September 2025 (elamipretide/Forzinity) for Barth syndrome — the first mitochondria-targeted therapeutic approved in the US, based on the TAZPOWER trial's multi-year improvements in 6-minute walk distance and cardiac biomarkers (confirmatory post-marketing study ongoing).

Across studies the mechanistic signal is consistent — SS-31 reaches its target, stabilizes the membrane, reduces byproducts, and improves efficiency — even where functional outcomes vary by indication.

SS-31 + MOTS-c + NAD+ Stack (MITT)

Mitochondrial performance depends on structure, signaling, and cofactor availability: SS-31 repairs structure (electrons flow cleanly), MOTS-c activates adaptive signaling (more mitochondria, better fuel choice), and NAD+ supplies the cofactor both run on. Better engines + more engines + fuel — the Mitochondrial Integration & Transformation Triad (MITT).

Side Effects and Safety

Common: transient warmth/flushing on early doses, brief nausea, mild fatigue during loading (reflecting the repair process). Rare: no dominant serious adverse events in published trials. The Barth-syndrome trials (extended treatment over years) showed acceptable tolerability, and the FDA approval reflects a positive benefit-risk assessment in a severely affected population.

SS-31 for Injury Recovery (Mitochondrial Stability)

The final bottleneck in injury recovery is often not tissue structure but mitochondrial instability under stress — you progress for a few sessions, then flare; fatigue becomes the limiter and the site feels biologically reactive rather than weak. SS-31 stabilizes mitochondrial output so repair consolidates instead of repeatedly re-inflaming — a stability layer, not a healing peptide. Use it after foundational repair (BPC-157/TB-500), metabolic support (NAD+/GHK-Cu/KPV), and hormonal timing (Tesamorelin) are in place but relapse under load persists; skip it if tissue is still cold/stiff (need more base repair), energy crashes at rest (need NAD+), or sleep is disrupted (Tesamorelin). It binds cardiolipin to tighten the energy chain, reduce ROS spikes, suppress NF-κB reactivation, and preserve glutathione. Injury dosing: load 5–10 mg daily 5–7 days, then 5–10 mg 2–3×/week for 4–8+ weeks; IV/IM in clinical settings (SubQ with guidance); inject alone, not mixed with other peptides. Cycles run 8–12 weeks; some repeat 4–6 week blocks every 6–12 months.